Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5393305 | 0.88 | OPRM1 (0.61) | OPRM1 | |
| SCHEMBL5398753 | 0.80 | DRD2 (0.47) | OPRM1 | |
| SCHEMBL4017396 | 0.74 | HCRTR1 (0.41) | OPRM1MAPTTP53OPRK1KCNH2 | |
| SCHEMBL5722464 | 0.74 | HCRTR1 (0.41) | OPRM1MAPTTP53OPRK1KCNH2 | |
| SCHEMBL5418712 | 0.72 | OPRM1 (0.52) | OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL5402482 | 0.70 | OPRM1 (0.56) | OPRM1 | |
| SCHEMBL5399099 | 0.70 | OPRM1 (0.58) | OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL5399531 | 0.69 | TSHR (0.46) | OPRM1OPRK1KCNH2OPRD1 | |
| SCHEMBL5397291 | 0.69 | OPRM1 (0.40) | OPRM1MAPTTP53OPRK1KCNH2 | |
| SCHEMBL5406464 | 0.69 | OPRM1 (0.58) | OPRM1GAAMAPTOPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241887-B2 | 3-azabicyclo[3.2.1]octane derivatives | PFIZER INC (US) | 2007-07-10 | — | — | US | claimed |
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | PFIZER INC | 2004-12-23 | — | — | US | claimed |
| US-7241887-B2 | 3-azabicyclo[3.2.1]octane derivatives | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885MGAM 4374/4885GAA 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.